GlassScriptPhysician profile
Oscar Chavez
NPI 1063880524
$14,319.25
in general payments reported to CMS, 2019-2025
43 companies · $3,894 in 2025
The $3,894 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,888 · 2022: $2,898 · 2023: $2,032 · 2024: $2,607 · 2025: $3,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,533.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,169.01 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $2,034.31 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,695.30 | 2021-2025 | |
| Novo Nordisk INC | $1,675.29 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,442.00 | 2021-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $854.37 | 2021-2025 | |
| Lilly USA, LLC | $496.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $450.87 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $407.77 | 2021-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Otsuka America Pharmaceutical, INC. | $321.46 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $320.39 | 2021-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $220.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.41 | 2021-2025 | Xifaxan |
| Cequr Corporation | $154.21 | 2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $149.03 | 2021-2024 | Nexletol |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.